Impressive time-related influence of the Dutch screening programme on breast cancer incidence and mortality, 1975-2006

International Journal of Cancer

Volumn 123, Issue 8, 2008, Pages 1929-1934

  Otten, Johannes D M ^a,c   Broeders, Mireille J M ^a,b,c   Fracheboud, Jacques ^c   Otto, Suzie J ^c   De Koning, Harry J ^c   Verbeek, André L M ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b National Expert and Training Centre for Breast Cancer Screening   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer screening; Incidence; Mortality; Trends

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; MORTALITY; NEOPLASM INVASIVENESS; NETHERLANDS;

EID: 51949108241     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23736     Document Type: Article

References (27)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
2. Vainto H, Bianchini F. Efficacy of screening by conventional mammography. Breast cancer screening. Lyon: IARC Press, 2002. 91-102.
3. de Koning HJ. Mammographic screening: evidence from randomised controlled trials. Ann Oncol 2003;14:1185-9.
4. Stockton D, Davies T, Day N, McCann J. Retrospective study of reasons for improved survival in patients with breast cancer in east Anglia: earlier diagnosis or better treatment. BMJ 1997;314:472-5.
5. Coebergh JW, Crommelin MA, Kluck HM, van BM, van der HF, Verhagen-Teulings MT. [Breast cancer in southeast North Brabant and in North Limburg; trends in incidence and earlier diagnosis in an unscreened female population, 1975-1986]. Ned Tijdschr Geneeskd 1990;134:760-5.
6. Jatoi I, Miller AB. Why is breast-cancer mortality declining? Lancet Oncol 2003;4:251-4.
7. Fracheboud J, Otto SJ, van Dijck J A, Breeders MJ, Verbeek AL, de Koning HJ. Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br J Cancer 2004;91: 861-7.
8. NETB (National Evaluation Team for Breast cancer screening). NETB Interim Report 2006. Rotterdam: Department of Public Health, Erasmus MC, University Medical Center Rotterdam; 2006.
9. [Internet] 2008 [cited 2008 February 25]. Available from: http://www.cbs.nl/en-GB/default.htm?Languageswitch-on.
10. [Internet] 2008 [cited 2008 February 25]. Available from: http://www.ikcnet.nl/page.php?id-97.
11. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-51.
12. [Internet] 2008 [cited 2008 February 25]. Available from: http://srab.cancer.gov/joinpoint/.
13. Otto SJ, Fracheboud J, Looman CW, Broeders MJ, Boer R, Hendriks JH, Verbeek AL, de Koning HJ. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 2003;361:1411-7.
14. Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr 2006;36:30-6.
15. Vervoort MM, Draisma G, Fracheboud J, van de Poll-Franse LV, de Koning HJ. Trends in the usage of adjuvant systemic therapy for breast cancer in The Netherlands and its effect on mortality. Br J Cancer 2004;91:242-7.
16. Nab HW, Hop WC, Crommelin MA, Kluck HM, Coebergh JW. Improved prognosis of breast cancer since 1970 in south-eastern Netherlands. Br J Cancer 1994;70:285-8.
17. Louwman WJ, Voogd AC, van Dijck JA, Nieuwenhuijzen GA, Ribot J, Pruijt JF, Coebergh JW. On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975-2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control 2008;19:97-106.
18. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992;339:1-15.
19. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992;339:71-85.
20. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
21. Levi F, Bosetti C, Lucchini F, Negri E, La VC. Monitoring the decrease in breast cancer mortality in Europe. Eur J Cancer Prev 2005;14:497-502.
22. de Koning HJ, Draisma G, Fracheboud J, de BA. Overdiagnosis and overtreatment of breast cancer: microsimulation modelling estimates based on observed screen and clinical data. Breast Cancer Res 2006;8:202.
23. Boer R, Warmerdam P, de KH, van OG. Extra incidence caused by mammographic screening. Lancet 1994;343:979.
24. NETB (National Evaluation Team for Breast cancer screening). National evaluation of mass screening for breast cancer in the Netherlands. Evaluation report XI (In Dutch with English summary). Rotterdam: Department of Public Health, Erasmus MC, University Medical Center Rotterdam; 2005.
25. Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 2003;39:1718-29.
26. MacMahon B. Epidemiology and the causes of breast cancer. Int J Cancer 2006;118:2373-8.
27. de Jong-van den Berg LT, Faber A, van den Berg PB. HRT use in 2001 and 2004 in The Netherlands - a world of difference. Maturitas 2006;54:193-7.